METHOD OF TREATING OR CONTROL OF HYPOPARATHYROIDUS USING PARATHROOID HORMONE (PTH) CONJUGATE Russian patent published in 2023 - IPC A61K38/29 A61K47/60 A61P5/18 

Abstract RU 2806753 C2

FIELD: medicine.

SUBSTANCE: invention discloses a method of treating or controlling hypoparathyroidism in a patient, wherein the method includes the step of administering an initial dose of 4.4 ± 0.3 nmol/day of a parathyroid hormone (PTH) conjugate, in which the PTH moiety is reversibly conjugated to a polymer constituent or a pharmaceutically acceptable salt thereof, or the step of administering an initial dose of 4.4 ± 0.3 nmol/day of a pharmaceutical composition containing the said PTH conjugate or a pharmaceutically acceptable salt thereof, and wherein the PTH conjugate has the following formula (IIf-i), where the unlabeled dotted line shows the attachment to the N-terminal amine functionality of a PTH moiety having the following sequence SEQ ID NO: 51, due to the formation of an amide bond; and the dotted line marked with an asterisk shows the addition to the component where m and p independently represent an integer in the interval and including 400–500.

EFFECT: technical result of the invention is the reduction of side effects due to a safe and effective initial dose of a long-acting PTH conjugate.

6 cl, 1 dwg, 1 tbl, 1 ex

Similar patents RU2806753C2

Title Year Author Number
RTN PRODRUGS 2017
  • Sprogee Kennett
  • Kleemann Feliks
  • Majtro Gijom
  • Krush Matias
  • Vegge Tomas
  • Tsettler Joakhim
RU2747316C2
DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE 2017
  • Kholten-Andersen, Lars
  • Sprogee, Kennett
  • Karpf, Devid Brajan
RU2777357C2
LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES 2020
  • Skands, Anja R.H.
  • Cleemann, Felix
  • Sorensen, Michael Duelund
  • Baron, Julia
  • Hoffmann, Eric
  • Sprogoe, Kennett
RU2817015C2
PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS 2017
  • Sprogee, Kennett
  • Kholten-Andersen, Lars
  • Karpf, Devid Brajan
RU2766959C2
CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS 2017
  • Kholten-Andersen, Lars
  • Miller Brajnkholt, Fibeke
  • Sprogee, Kennett
RU2768747C2
CNP PRODRUGS 2016
  • Sprogoe, Kennett
  • Hersel, Ulrich
  • Rau, Harald
  • Wegge, Thomas
  • Faltinger, Frank
  • Cleemann, Felix
  • Kaluza, Nora
  • Bernhard, Ana
  • Buba, Annette
  • Woods, Tom
RU2824988C1
STABLE LOCAL DRUG LEVELS FOR INNATE IMMUNITY AGONISTS 2020
  • Rosen, David B
  • Zuniga, Luis
  • Punnonen, Juha
  • Holten-Andersen, Lars
  • Sprogoe, Kennett
  • Yang-Malten, Yang
  • Lessmann, Torben
  • Bisek, Nicola
  • Weisbrod, Samuel
  • Stark, Sebastian
  • Voigt, Tobias
RU2817710C2
PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION 2018
  • Stark, Sebastyan
  • Knappe, Tomas
  • Rau, Kharald
  • Bisek, Nikola
  • Laufer, Burkhardt
  • Vajsbrod, Semyuel
  • Vojt, Tobias
  • Fukh, Dzhermen
  • Kenig, Patrik
  • Li, Chingvej, Vivan
  • Yadav, Daniela Bumbaka
RU2812787C2
IL-2 CONJUGATES 2019
  • Sprogoe, Kennett
  • Rau, Harald
  • Knappe, Thomas
  • Bisek, Nicola
  • Laufer, Burkhardt
RU2809259C2
BENZAZEPINE COMPOUNDS, CONJUGATES AND THEIR USE 2018
  • Coburn Craig Alan
  • Baum Peter Robert
  • Smith Sean Wesley
RU2780334C2

RU 2 806 753 C2

Authors

Sprogoe, Kennett

Karpf, David Brian

Strange, Claus

Dates

2023-11-07Published

2019-05-17Filed